Redeye comments on Fluoguide’s Q2 2024 report, following its recent cSEK60m directed share issue that came at shareholder-friendly terms. We will closely watch FG001’s progression in clinical development and business development news in coming quarters. We do some housekeeping in our estimates and valuation.